Hyperglycaemia is the diagnostic criterion and a main prognostic parameter in diabetes. Epidemiological and intervention studies have defined the target values for glycaemic control, and there is general consensus that antihyperglycaemic treatment should aim at reducing HbA 1c levels below 7%. In order to achieve this goal it is important that the entire daily glucose profile is reduced. This can be accomplished only by therapies designed to tackle both basal and postprandial hyperglycaemia. However, an increasing bulk of data suggest that postprandial glucose may be even more deleterious that fasting hyperglycaemia in determining the risk for long-term diabetic complications. A strong association has been recognized for a long time between 2 h post-oral glucose tolerance test (OGTT) glucose levels and mortality and cardiovascular disease. Although these data cannot be directly extrapolated to daily life conditions, excessive glucose excursion after the ingestion of a meal seems to be a common phenomenon even in treated diabetic individuals. Rapid-acting insulin analogues, used as the prandial component insulin replacement therapy and short-acting insulin secretagogues, targeting postprandial glucose control, may have a useful new role to play in the management of diabetes mellitus. These interventions have successfully limited postprandial glycaemic exposure, but evidence is still awaited that these outcomes will translate into prognostic benefits. Other components have to be considered in the search for strict glycaemic control. Diabetic patients with similar HbA 1c values may differ in term of glucose stability. Data are available that suggest that patients with larger glucose fluctuation within the day and from day-to-day may be exposed to greater risk of diabetic complications. Therefore, in designing strategies to reduce the burden of diabetic complication both a quantitative effect of hyperglycaemia (fasting, postprandial hyperglycaemia, and HbA 1c ) as well as a qualitative component (glucose stability) should be taken into account.
Hyperglycaemia and diabetic complication
While Type 1 and Type 2 diabetes mellitus differ fundamentally in their aetiology and epidemiology, they are associated with a similar spectrum of long-term sequelae. Both can lead to microvascular complications with the potential to devastate quality of life, and both are characterized by a high risk of cardiovascular morbidity and mortality: some 2 -11-fold that of the age-matched background population. 1 -3 The syndrome of diabetes mellitus is very often associated with marked increases in other well known parameters of cardiovascular risk including hypertension, hypertriglyceridaemia and low HDL-cholesterol levels, and these factors appear to be even more predictive of a poor cardiovascular prognosis in the setting of chronic hyperglycaemia. 3, 4 Nearly 80% of patients with Type 2 diabetes are currently expected to die from cardiovascular disease. 5 Although these multiple metabolic alterations contribute to the overall risk of diabetic complications, hyperglycaemia still remains the hallmark of diabetes mellitus. Plasma glucose level is the key diagnostic criterion for diabetes and it is strongly associated with the risk of developing micro-and macrovascular complications. This association has been appreciated for a long time, but it became fully apparent as soon as an integrated marker for overall glucose exposure such as HbA 1c was made available. 6 For example, in a Finnish study involving 133 middle-aged newly diagnosed Type 2 diabetic patients, 10 y cardiovascular mortality increased three-fold by tertiles of plasma glucose and HbA 1c . 7 Similar results were obtained in older Type 2 diabetic patients, with HbA 1c being a significant predictor for coronary heart disease. 8 More recently, the UKPDS has indicated that the incidence of clinical complications of Type 2 diabetes is significantly associated with glycaemia and HbA 1c . 9 From such strong relationships one could infer that reduction of HbA 1c by intervention should lead to a lower number of cardiovascular events. The epidemiological analysis of the results of the UKPDS has indicated that each 1% reduction in updated HbA 1c was associated with reduction in risk of 21% for any endpoint related to diabetes, 21% for deaths related to diabetes, 14% for myocardial infarction, and 37% for microvascular complications. 9 Glycated haemoglobin provides an integrated measure of glucose exposure during the day with both interprandial and postprandial glucose levels contributing to its absolute level, as indicated by the high degree of correlation between HbA 1c and fasting, 10, 11 preprandial, 12 and postprandial 13 plasma glucose concentrations. However, the relative contribution of fasting vs postprandial glucose in determining HbA 1c is worth some consideration.
Role of fasting and postprandial glucose in determining HbA 1c
Fasting plasma glucose correlates with both mean daily plasma glucose and HbA 1c . Because of this, fasting blood glucose is often taken as a reflection of overall glycaemic control. This approach was adopted by the UKPDS, where the target for treatment was fasting plasma glucose concentration: only at the end of the study was HbA 1c used to assess the relationship between glycaemic control and complications.
14 This approach assumes fasting plasma glucose is the main determinant of HbA 1c . Following the first year of follow-up, glycaemic control in the UKPDS progressively deteriorated suggesting that a delay rather than a prevention of events was to be expected. Figure 1 presents the percentage change in fasting plasma glucose and HbA 1c following the initial improvement in the intensive treatment and clearly demonstrates that the two curves progressively separate. This suggests that fasting plasma glucose is not the only parameter affecting HbA 1c , and the gap between the two lines might be explained by unmet post-meal glucose control. Fasting plasma glucose and HbA 1c values that do not correspond are not rare in diabetic patients. 15 Although this may simply represent the difference between an acute parameter (fasting plasma glucose) and a marker for long-term glycaemic control (HbA 1c ), it has been suggested that abnormally high and sustained postmeal hyperglycaemia can account for discrepancy between the two parameters. 16 By defining the postprandial phase as the period during which net glycogen accretion occurs, it can be calculated that this phase can last up to 5 h. 17 Assuming three meals are consumed during a typical day, it can readily be appreciated that the postprandial phase can cover 60 -70% of the day, 18 and easily affect overall glycaemic control and HbA 1c .
Some calculation of the relative contribution of fasting and postprandial hyperglycaemia can be made. The glycation process is the result of the overall exposure of body proteins to glucose. This can be quantified as the area under the curve of 24 h plasma glucose profile. Within this area, the percentage contribution of basal plasma glucose can be calculated as the area below the line connecting the fasting plasma glucose values on two consecutive days, while the area above this line accounts for postprandial glucose ( Figure 2 ). In our example, the overall glucose exposure will be two-fold greater in the diabetic patients as compared to the normal individual (65 vs 28 g=24 h). Although postprandial glucose can contribute to overall effect with a substantial absolute amount of glucose, percentage wise there is not much difference between the diabetic and the normal subject (18 vs 12%). In the early stage of the disease, In search of normoglycaemia in diabetes S Del Prato when hyperglycaemia mainly occurs after meals, postprandial glucose can account for 30 -40% of overall glucose exposure. As such it is an ideal target for intervention.
With the progressive worsening of glycaemic control and progressive rise of fasting plasma glucose, it becomes apparent that a more comprehensive therapeutic approach is required to reduce glucose exposure and, therefore, HbA 1c . Several intervention studies can be cited to support this view.
In the context of basal-bolus therapy, many studies have shown that particularly effective postprandial glucose control is achieved (without an increase in the risk of hypoglycaemia) when the rapid-acting insulin analogues insulin aspart 19 -21 or insulin lispro 22 -24 are used instead of soluble human insulin as the prandial component of therapy alongside protaminated (NPH) basal insulin ( Figure 3 ). Insulin aspart and insulin lispro are genetically engineered to dissociate from the hexameric into the monomeric state more readily at high concentrations in the subcutis than native human insulin; monomers are more rapidly absorbed into the circulation. 25 Long-term studies have established the benign safety profile of these agents, 25 and together with crossover studies 23, 26, 27 collectively demonstrate that aspart and lispro, as well as improving postprandial control, can reduce hypoglycaemia, although the improvement of HbA 1c remains limited. In Type 2 diabetic patients with poor glycaemic control (HbA 1c 9.0%) the use of combination therapy with sulphonylurea to reduce fasting plasma glucose and three injections of insulin lispro at meal time was associated with a significant reduction of both fasting and 2 h postprandial glucose levels, leading to a dramatic reduction in HbA 1c (7.1% after 4 months). 28 Such a beneficial effect is retained irrespective of the strategy employed to ensure basal insulinization. Insulin lispro in combination with bed-time NPH-insulin or sulphonylurea resulted in a better overall glycaemic control when compared with NPH plus sulphonylurea. 29 Conversely, accurate basal insulin replacement as can be achieved with long-acting insulin glargine does not result in major changes in HbA 1c . 30 It is likely that concomitant reduction in postprandial glucose excursion may ensure rewarding results. That both basal and postprandial glycaemia need to be tackled is supported by results obtained in intensively treated Type 1 diabetic patients. In Type 1 diabetic patients with an already excellent glycaemic control (HbA 1c of 6.8%), Lalli et al Figure 3 Mean eight-point blood glucose profiles in a cohort with Type 1 diabetes at baseline and after 6 and 12 months of treatment with insulin aspart or regular human insulin. *Between-treatment difference, P < 0.05. Reproduced, with permission from the American Diabetes Association. Copyright# 2000 American Diabetes Association.
Figure 4
Hazard ratio for mortality as a function of fasting and 2 h glucose categories in the DECODE database. In the DECODE study, mortality risk increased with post-glucose load plasma glucose concentration regardless of fasting plasma glucose levels. The converse relationship did not apply ie at a given level of post-glucose load, fasting glucose was not a determinant of risk. Data adapted from DECODE Study Group. 40 In search of normoglycaemia in diabetes S Del Prato managed to gain a further 0.4% reduction in HbA 1c (P < 0.05) by combining fast-acting insulin analogues and accurate basal insulin replacement by using multiple administration of NPH-insulin. 31 A more comprehensive approach aimed at controlling both basal and postprandial glucose level may also be required to maintain glycaemic control over a longer time. The Kumamoto study 32 differs from the UKPDS in terms of size and ethnic population. The two studies were also different because of the treatment strategies (intensive treatment with bed-time insulin or oral hypoglycaemic agents vs conventional treatment, mainly diet, in the UKPDS; multiple vs conventional insulin injection regimens in the Kumamoto study), and also in terms of therapeutic goals. While fasting plasma glucose concentration was the only therapeutic goal in the UKPDS, in the Japanese study goals were set in terms of fasting, post-meal plasma glucose, and Mean Amplitude Glucose Excursion (MAGE). The recently reported 8 y followup of the latter study has confirmed the maintenance of excellent metabolic control in intensively treated patients (HbA 1c 7.0 vs 9.2%), while a smaller number of cardiovascular events was recorded, although no statistical significance could be ascertained due to the still limited number of events. 33 In conclusion, while HbA 1c remains the gold standard for monitoring glycaemic control in diabetic patients and provides the current evidence base for the benefits of longterm 'good' control, both fasting and postprandial glucose should represent well defined targets for therapy (Table 1) , as clearly indicated by both the International Diabetes Federation 34 and the American Association of Clinical Endocrinologists. 35 Beyond HbA 1c : the epidemiological 'smoking gun' of postchallenge blood glucose Although no doubt exists on the critical significance of HbA 1c , the possibility of independent association of fasting and postprandial glucose concentration with overall and cardiovascular mortality, or the role of components of glycaemic control that are not reflected by HbA 1c , should be considered.
In the meta-analysis of Coutinho et al, 36 a total of 20 studies including 95 783 non-diabetic subjects and 3707 cardiovascular events during a mean follow-up period of 12.4 y, both fasting and 2 h post-oral glucose tolerance test (OGTT) plasma glucose levels were independently associated with an increased risk for cardiovascular events. The distinction between an independent role of fasting vs postchallenge plasma glucose levels has become a hot issue following the report of the Expert Committee on the Classification and Diagnosis of Diabetes Mellitus of the American Diabetes Association. 37 While suggesting that fasting plasma glucose measurements should take over from the OGTT as the diagnostic test for diabetes, a new category at risk to develop diabetes was identified: impaired fasting glucose (IFG; 6.1 -7 mmol=l or 110 -126 mg=dl). Nonetheless, it was appreciated that IFG and impaired glucose tolerance (IGT; 2 h OGTT plasma levels 7.8 -11.1 mmol=l or 140 -200 mg=dl) do not identify the same population and there is limited overlap between the two groups of individuals. 38 This observation has triggered extensive epidemiological research in the attempt to define whether IFG and IGT patients also differ in terms of cardiovascular risk. In the Funagata Diabetes Study, 39 2534 subjects over 40 y of age entered a 7 y follow-up for estimation of survival rate, after being classified as having normal fasting glucose (NFG), IFG, IGT or overt diabetes. After seven observed years, the cumulative survival rates from cardiovascular disease of IGT and diabetes were 0.962 and 0.954, respectively, both significantly lower than that of NGT (0.988). The Cox's proportional hazard model analysis showed that the hazard ratio of IGT to NGT on death from cardiovascular disease was 2.219 (95% CI 1.076 -4.577). However, the cumulative survival rate of IFG from cardiovascular disease was 0.977, not significantly lower than that of NFG (0.985). The Cox's hazard ratio of IFG to NFG on death from cardiovascular disease was 1.136 (0.345 -3.734), which was not significant either. Thus, at least in this Japanese population, IGT was a risk factor for cardiovascular disease, while IFG was not.
DECODE stands for Diabetes Epidemiology: Collaborative analysis Of Diagnostic criteria in Europe and it includes OGTT data from more than 25 000 subjects collected from all over Europe and used to analyse the respective association of fasting and 2-hr OGTT plasma glucose levels with overall 40 and cardiovascular mortality. 1 The DECODE study indicated that an increased mortality risk was associated with 2 h postload plasma glucose levels to a much greater extent than with FPG (Figure 4) . 40 The latter, after adjustment for the 2 h glucose value, lost any association with all-cause mortality. After adjusting for possible confounders, the excess death for cardiovascular disease was not affected by progressive increase in fasting plasma glucose levels when subjects with normal glucose tolerance were considered. The greatest excess mortality occurred in subjects with normal fasting plasma glucose concentration (FPG < 6.1 mmol=l) but impaired glucose tolerance. 41 These results are in agreement with findings from other epidemiological studies. In the prospective Whitehall study of 18 000 middle-aged men, 2 h post-OGTT plasma glucose levels above the 95th centile were predictive of a 2-fold increase in coronary heart disease (CHD) mortality after In search of normoglycaemia in diabetes S Del Prato 7.5 y. 42 A meta-analysis of these data and those obtained in the Paris Prospective and Helsinki Policemen studies again revealed post-OGTT glucose levels to be an independent risk factor for cardiovascular disease. 43 The Honolulu Heart Program, a study of cardiovascular risk in middle-aged men of Japanese ancestry living in the USA, also implicated postglucose load glucose as an important risk factor. 44 More than 6000 men without diabetes at baseline were followed for 12 y. When they were stratified into quintiles by baseline 1 h post-OGTT circulating glucose concentration, there were incremental increases in the rates of fatal CHD events and the combined endpoint of fatal CHD or non-fatal myocardial infarction (MI). The age-adjusted incidence of fatal CHD was three times higher in the fifth quintile than the first. Post-OGTT glucose was an independent and significant (P < 0.001) predictor of risk: the trend being linear and continuous. In another study, more than 2300 Dutch subjects without known diabetes and aged 50 -75 y were followed over 8 y. 45 Fasting plasma glucose predicted cardiovascular mortality only when values were in the diabetic range, but there was a statistically significant linear correlation between risk and 2 h post-OGTT blood glucose at all levels. Exclusion of patients with newly diagnosed diabetes or pre-existing cardiovascular disease from the analysis showed a 5 mmol=l increase in post-OGTT blood glucose to be associated with a relative risk for cardiovascular mortality of 3.4 (P < 0.05). This relative risk was still statistically significant (3.0, P < 0.05) when adjusted for other cardiovascular risk factors.
Collectively, these studies support the concept that excessive glucose excursion after the ingestion of an oral glucose load is associated with an independent risk for cardiovascular disease that is significantly greater than the one associated with fasting plasma glucose. Based on these results it has been suggested that individuals with isolated postchallenge hyperglycaemia should be identified and that post-meal glucose concentration should be a target for therapy in the attempt to reduce the cardiovascular risk of these subjects.
From postchallenge to postprandial glucose
The epidemiological analysis is almost entirely based on the OGTT. From these data it is tempting to assume that excessive glucose increments occurring after the ingestion of a mixed meal may carry a similarly negative prognosis as IGT. However, whether subjects with excessive glucose excursion in response to an OGTT also have exaggerated glucose increase after a mixed meal remains to be established. In a group of 36 Type 2 diabetic patients Wolever et al 46 observed a strong correlation between 2 h plasma glucose after an OGTT and following a standard mixed meal (r ¼ 0.97; P < 0.0001). Even in established diabetic patients on treatment postprandial glucose levels during daily life condition may be poorly controlled. Bonora et al 12 have assessed daily glucose profile in 856 Type 2 diabetic patients on different treatments (diet, sulphonylureas, metformin, or the combination of the two). Irrespective of treatment, a total of 67.4% of the patients had an exaggerated elevation of plasma glucose ( > 2.2 mmol=l) either after breakfast or after lunch. High postglucose load levels are also found in patients with HbA 1c values below 7.0%. In the diabetic population of the NHANES III, 39% of patients with HbA 1c < 7.0% had 2 h OGTT plasma glucose levels higher than 11.1 mmol=l, a percentage increasing to 99% in subjects with HbA 1c 7.0 -7.9%. 47 The excessive post-meal glucose levels of diabetic patients have been associated with a greater risk for cardiovascular disease as compared to fasting plasma glucose concentrations. Postprandial glucose, measured 1 h after patients' normal breakfasts, was shown to be an important predictor of risk in the prospective Diabetes Intervention Study (DIS), which followed a cohort of more than 1100 patients with newly diagnosed Type 2 diabetes. 48 Patients dying during an 11 y follow-up period had a significantly higher mean postprandial glucose level at baseline than survivors (8.9 vs 8.4 mmol=l, P < 0.01). No such disparity was found for fasting glucose. Multivariate analysis showed postprandial, but not fasting, plasma glucose to be an independent risk factor for mortality. Patients were stratified according to European criteria for 'good', 'borderline' and 'poor' control of fasting plasma glucose (FPG), postprandial glucose (PPG), triglycerides, cholesterol, blood pressure and body mass index (BMI). There was a trend for mortality and myocardial infarction rates to correlate with worsening control in each parameter, but these trends only reached statistical significance in the case of postprandial glucose. Poor postprandial control was associated with a relative mortality risk of 2.24 (P < 0.01), while fasting glucose was not associated with a significant trend for either outcome.
The causal mechanism behind the contribution of acute hyperglycaemia to long-term diabetic complications remains to be elucidated, but different metabolic pathways that may contribute to development of micro-and macroangiopathy are activated by hyperglycaemia. 49 In normal subjects, 2 h elevation of plasma glucose by a hyperglycaemic clamp causes a sustained activation of several PKC isoforms and of PKC-b2 in particular. 50 Post-meal glucose excursions are directly correlated with post-meal levels of highly reactive molecules (2-deoxyglucosone, methylglyoxal), 51 potent triggers for dycarbonyl and oxidative stress, and AGE formation. 52 Of note is the fact that carbonyl stress can be generated not only by excessive glucose excursion but also by increased levels of lipids and amino acids, suggesting a more complex post-meal metabolic condition. The negative effects of acute hyperglycaemia are the likely result of labile nonenzymatic glycation and production of free radicals with ensuing oxidative stress. 53 Acute hyperglycaemia causes endothelial dysfunction, 54 possibly through a reduction of nitric oxide availability. 55 In a recent study, Nappo et al 56 have reported that an oxidative mechanism mediates endothelial activation, which is more pronounced following a high-fat meal. AGEs
In search of normoglycaemia in diabetes S Del Prato affect protein function and gene expression. AGEs, PKC and oxidative stress are potent stimuli for the production of reactive oxygen species (ROS), all common culprits in vascular pathology. PKC activation interferes with cell signalling, stimulates the conversion of smooth muscle and endothelial cells to a proliferative phenotype in peripheral conduit vasculatures, and causes release of vasoconstrictor substances. 57 These alterations can explain the impairment in metacholine-induced vasodilatation the acute elevation of plasma glucose concentration can cause even in normal individuals. 54 The implication of PKC activation by acute glucose increase in the impairment of endotheliumdependent vasodilatation has been recently demonstrated by prevention of this effect by PKCb inhibitor LY33353. 58 Mealtime glucose excursions exert marked effects on the coagulation process. 59 Hence, the acute changes in plasma glucose concentrations may result in a thrombophilic condition as platelet adhesion is also enhanced by hyperglycaemia. 55 The atherogenic process may be facilitated by the increase in adhesion proteins triggered by hyperglycaemic peaks. 60 In summary, the post-meal phase is a complex metabolic condition where acute increases not only in plasma glucose, but also in lipids and, possibly, amino acids, can trigger an array of cellular and molecular mechanisms that may lead to vessel wall stress and, in the long term, diabetic angiopathy. The potential long term health benefits of controlling metabolism during this phase look attractive, but as yet remain to be demonstrated.
The elusive component of glycaemic control
Epidemiological and intervention studies have clearly indicated the importance of HbA 1c in predicting longterm diabetic complications. Nonetheless, HbA 1c may not completely explain the risk. In a further analysis of the DCCT results, a difference between intensive and conventional treatment groups in the effects of time was observed such that the risk for retinopathy progression was different between the groups at similar mean HbA 1c values:
61 the incidence of diabetic retinopathy was greater in patients on conventional treatment. It was speculated that HbA 1c may not be the most complete expression of the degree of glycaemia. The DCCT investigators proposed that other features of diabetic glucose control, which are not reflected by HbA 1c may add to or modify the risk of complications. One possibility is that the risk of complications may be more highly dependent on the extent of postprandial glucose excursions or be influenced by counterregulatory hormonal responses to hypoglycaemia. In other words, since HbA 1c is an integrated measure of overall glucose exposure, similar HbA 1c values can be generated by different glucose profiles ( Figure 5 62 In the setting of the Verona Diabetes Study, 63 566 elderly patients with Type 2 diabetes were followed up for 5 y to assess mortality and causes of death. All FPG determinations of the 3 y preceding the follow-up available in the clinical records were collected and analysed. Patients were grouped in tertiles of mean FPG, CV-FPG, and the slope of FPG. These parameters of glucose control, as well as sex, age, duration of diabetes, insulin treatment, cigarette smoking, hypertension, and total cholesterol, were included in a multivariate analysis of mortality. During the follow-up, 63 men and 128 women died. Diabetes-and malignancy-related mortality were not independently associated with any parameter of glucose control, whereas cardiovascular-related mortality was independently associated with CV-FPG (P ¼ 0.007) but not with the mean or the slope of FPG. A significant increase in P-selectin serum levels has been reported in Type 2 diabetic patients with high (coefficient of variation, CV of fasting plasma glucose > 25%) as compared to those with low plasma glucose variability (CV < 10%). 64 In vitro studies corroborate these findings. Rapid reduction of glucose concentration in the medium of cultured capillary pericytes is sufficient to cause cell shrinkage and nuclear condensation associated with DNA fragmentation and loss of cell viability. 65 Periodic high extracellular glucose (5 -25 mM glucose) enhances the production of collagens III and IV by cultured mesangial cells to a much greater extent than constant high glucose concentration (25 mM) does. 66 In cultured tubulointerstitial cells, increased glucose Figure 5 Diabetic patients with similar HbA 1c may differ in terms of glucose stability. In the first example, HbA 1c of 7.5% is generated by smooth oscillation of plasma glucose levels around the mean value, while in the second example the glucose excursions are much greater still leading to the same value of HbA 1c .
In search of normoglycaemia in diabetes S Del Prato concentrations affect cell growth, collagen synthesis and cytokine secretion. These effects are enhanced following intermittent exposure to high glucose (6.1 -25 mM). 67 Incubation of Human Umbilical Vein Endothelial Cells (HUVEC) in the presence of 20 mM glucose led to increased DNA fragmentation, a marker for apoptosis, but an even greater fragmentation was documented when glucose was presented to the cells in a cycling manner, simulating glucose fluctuation. 68 Collectively, these results indicate that plasma glucose instability exerts biological effects that contribute to the risk of long-term diabetic complications beyond the effect of absolute glucose level. We therefore, propose that plasma glucose may cause long-term complications via a quantitative effect that can be reflected by HbA 1c , and a qualitative defect due to glucose instability, as schematically represented in Figure 6 .
From a simple parameter to a complex strategy
The deleterious effect of hyperglycaemia is likely to be exerted both in a chronic and sustained way reflected by HbA 1C , as well as through fluctuation of plasma glucose levels. Glucose variability can be largely attributed to postmeal glucose excursion and it may differentiate among diabetic patients with comparable HbA 1c , thus contributing to different glucose susceptibility to complications. Epidemiological evidence supports a relationship of post-load (and post-meal) plasma glucose and CV mortality and morbidity, while in vitro studies clearly demonstrate that glucose excursions can trigger biological mechanisms involved in the pathogenesis of diabetic complications. Unfortunately, data from intervention studies are still limited.
It is very likely that not only glucose but also the excursion of other metabolic parameters can contribute to overall risk of long-term complications. For instance, both postprandial glucose and postprandial triglycerides are independently associated with arterial intima medial thickness (IMT), a marker for cardiovascular risk. 69, 70 In view of this complex picture, a complex and comprehensive approach must be envisaged. Strict glycaemic control will require more focus on postprandial hyperglycaemia. To this purpose, replication of the early phase insulin release appears to be a rational approach. 71 This can be accomplished by quick-acting secretagogues (repaglinide, nateglinide) as long as b-cell mass and function are retained, while rapid-acting insulin analogues (aspart, lispro) may be required if reconstruction of the insulin profiles is needed. Concomitant use of insulin sensitizers may be of value because they may help control fasting and interprandial glucose levels. Moreover, insulin sensitizers may be important in tackling the complex postprandial phase, which includes not only glucose, but also lipid and amino acid excursions. 72 The complexity of the metabolic alteration in diabetes must be fully recognized. Although hyperglycaemia is a simple diagnostic criterion and it plays a main role in the pathogenesis of diabetic micro-and macrovascular complications, other factors (dyslipidemia, arterial hypertension, obesity, impaired coagulation and fibrinolysis, endothelial dysfunction, inflammatory responses, and many others) do contribute to the overall risk in diabetic individuals. Therefore, even if plasma glucose is a simple parameter, effective treatment of diabetes demands full consideration of the qualitative and quantitative aspects of glycaemic control as well as all of the components of the diabetic syndrome. In search of normoglycaemia in diabetes S Del Prato
